These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20553205)

  • 21. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
    Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
    Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer.
    Clare J
    Future Oncol; 2013 Dec; 9(12 Suppl):1. PubMed ID: 24195522
    [No Abstract]   [Full Text] [Related]  

  • 24. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    Giuliani J; Bonetti A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ; Dalton H; Benjamin I; Tanović A
    Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
    Krasner CN; Poveda A; Herzog TJ; Vermorken JB; Kaye SB; Nieto A; Claret PL; Park YC; Parekh T; Monk BJ
    Gynecol Oncol; 2012 Oct; 127(1):161-7. PubMed ID: 22765965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    Colombo N
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S12-6. PubMed ID: 21540666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trabectedin for the therapy of ovarian cancer.
    Evangelisti G; Barra F; D'Alessandro G; Tantari M; Stigliani S; Della Corte L; Bifulco G; Ferrero S
    Drugs Today (Barc); 2020 Oct; 56(10):669-688. PubMed ID: 33185631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing the chances for platinum-sensitive ovarian cancer patients.
    González A
    Future Oncol; 2013 Dec; 9(12 Suppl):29-35. PubMed ID: 24195528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
    Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
    Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
    Markman M
    Gynecol Oncol; 2011 Aug; 122(2):462; author reply 462-3. PubMed ID: 21620447
    [No Abstract]   [Full Text] [Related]  

  • 33. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
    Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
    Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
    Romero I; López-Guerrero JA; Pignata S
    Expert Rev Anticancer Ther; 2021 Oct; 21(10):1089-1095. PubMed ID: 34128757
    [No Abstract]   [Full Text] [Related]  

  • 36. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
    Boccia SM; Sassu CM; Ergasti R; Vertechy L; Apostol AI; Palluzzi E; Fagotti A; Scambia G; Marchetti C
    Drug Des Devel Ther; 2024; 18():2021-2032. PubMed ID: 38863768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
    Lorusso D; González-Martín A; Ray-Coquard I
    Future Oncol; 2021 Jan; 17(3s):9-19. PubMed ID: 33353406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin.
    González-Martín A; du Bois A
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):3-10. PubMed ID: 27797624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
    Khokhlova SV; Cherkasova MV; Orel NF; Limareva SV; Bazaeva IIa; Gorbunova VA
    Vestn Ross Akad Med Nauk; 2013; (11):115-21. PubMed ID: 24640740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trabectedin: Supportive care strategies and safety profile.
    Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.